--12-31false0001076930Q3UnlimitedUnlimitedhttp://www.novanta.com/20230929#RestructuringChargesAndAcquisitionRelatedCostsP1Yhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrentzero yearsseven year0001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2023-01-012023-09-290001076930country:US2023-07-012023-09-290001076930novt:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-290001076930novt:OtherCountriesMember2022-07-022022-09-300001076930us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyMember2023-01-012023-09-290001076930us-gaap:CommonStockMember2022-09-300001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2022-07-022022-09-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-12-310001076930novt:EquityIncentivePlanTwentyTenMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2023-09-2900010769302022-09-300001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2022-01-012022-09-300001076930country:CN2022-07-022022-09-300001076930us-gaap:ForeignExchangeForwardMember2023-09-290001076930novt:RestOfEuropeMember2023-07-012023-09-290001076930us-gaap:CustomerRelationshipsMember2022-12-310001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FirstAmendmentRevolvingCreditFacilityMember2020-03-270001076930novt:EquityIncentivePlanTwentyTenMembersrt:MinimumMembernovt:HybridPsusMember2023-01-012023-09-290001076930us-gaap:FairValueInputsLevel2Membernovt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310001076930country:CN2023-07-012023-09-290001076930novt:ARGESGmbHMember2023-01-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2023-09-290001076930novt:AdvancedIndustrialMember2023-07-012023-09-290001076930novt:PrecisionMedicineAndManufacturingMember2023-09-290001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2022-01-012022-09-3000010769302022-01-012022-09-300001076930us-gaap:OtherRestructuringMember2023-09-290001076930novt:EquityIncentivePlanTwentyTenMembernovt:DeferredStockUnitsMember2022-12-310001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2023-07-012023-09-290001076930novt:BrianSYoungMember2023-09-2900010769302022-07-010001076930country:DE2022-07-022022-09-300001076930novt:UnallocatedCorporateAndSharedServicesMembernovt:FiscalYearTwentyTwentyTwoMember2023-07-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMembersrt:MinimumMembernovt:MarketBasedPsusMember2023-01-012023-09-290001076930novt:RoboticsAndAutomationMember2022-12-310001076930novt:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-12-302019-12-310001076930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930country:US2022-01-012022-09-300001076930novt:SeveranceFacilityRelatedAndOtherChargesMembernovt:FiscalYearTwentyTwentyMember2023-01-012023-09-290001076930srt:MaximumMembernovt:EquityIncentivePlanTwentyTenMembernovt:MarketBasedPsusMember2023-01-012023-09-290001076930us-gaap:CostOfSalesMember2023-07-012023-09-290001076930us-gaap:TrademarksAndTradeNamesMember2023-09-290001076930srt:MinimumMember2023-09-290001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:DirectorMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyMembernovt:UnallocatedCorporateAndSharedServicesMember2022-01-012022-09-300001076930novt:ProfessionalAndConsultingFeesMember2023-07-012023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-022022-09-300001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:PerformanceSharesMember2022-12-310001076930novt:AttainmentBasedPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MaximumMember2023-01-012023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930novt:RoboticsAndAutomationMember2023-09-290001076930us-gaap:FairValueInputsLevel3Member2023-09-290001076930novt:MedicalSolutionsMember2023-09-290001076930us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:AdditionalPaidInCapitalMember2023-06-300001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2022-07-012022-09-300001076930novt:MedicalMember2022-01-012022-09-300001076930us-gaap:RetainedEarningsMember2023-09-290001076930novt:ARGESGmbHMember2022-12-310001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-290001076930us-gaap:OtherRestructuringMember2023-01-012023-09-290001076930us-gaap:CommonStockMember2023-01-012023-09-2900010769302023-04-012023-06-300001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-302019-12-310001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2022-07-022022-09-300001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:CostOfSalesMember2023-09-290001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:TermLoanMember2019-12-310001076930novt:PrecisionMedicineAndManufacturingMember2022-12-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2023-02-012023-02-280001076930novt:EquityIncentivePlanTwentyTenMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2023-01-012023-09-2900010769302023-06-300001076930srt:MaximumMember2023-01-012023-09-290001076930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930novt:RestOfAsiaPacificMember2022-01-012022-09-300001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2023-01-012023-09-290001076930us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:AccountingStandardsUpdate201409Member2022-12-310001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:FiscalYearTwentyTwentyMember2023-07-012023-09-290001076930novt:FiscalYearTwentyTwentyMembernovt:UnallocatedCorporateAndSharedServicesMember2022-07-022022-09-3000010769302022-12-310001076930novt:MedicalMember2022-07-022022-09-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:TermLoanMember2020-03-012020-03-310001076930novt:FiscalYearTwentyTwentyMembernovt:MedicalSolutionsMember2022-01-012022-09-300001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-010001076930novt:FiscalYearTwentyTwentyMembernovt:MedicalSolutionsMember2022-07-022022-09-300001076930novt:ARGESGmbHMember2020-12-310001076930us-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930novt:FiscalYearTwentyTwentyTwoMember2022-01-012022-09-300001076930us-gaap:FacilityClosingMember2023-01-012023-09-290001076930us-gaap:AdditionalPaidInCapitalMember2022-09-300001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2023-09-290001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2023-01-012023-09-290001076930us-gaap:CorporateNonSegmentMember2023-07-012023-09-290001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-290001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-290001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930novt:RestOfEuropeMember2022-07-022022-09-300001076930us-gaap:AdditionalPaidInCapitalMember2022-07-010001076930novt:BrianSYoungMember2023-01-012023-09-290001076930us-gaap:RetainedEarningsMember2022-07-022022-09-300001076930us-gaap:AccountingStandardsUpdate201409Member2023-09-290001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2023-01-012023-09-290001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2022-07-022022-09-300001076930novt:FiscalYearTwentyTwentyTwoMembernovt:MedicalSolutionsMember2023-07-012023-09-290001076930us-gaap:AdditionalPaidInCapitalMember2021-12-310001076930novt:FiscalYearTwentyTwentyMember2022-07-022022-09-3000010769302022-07-022022-09-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-310001076930srt:MinimumMembernovt:FiscalYearTwentyTwentyTwoMember2023-09-290001076930us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930us-gaap:CostOfSalesMember2022-01-012022-09-300001076930us-gaap:RetainedEarningsMember2022-01-012022-09-300001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2022-07-022022-09-300001076930us-gaap:FacilityClosingMember2023-09-290001076930us-gaap:RetainedEarningsMember2021-12-310001076930novt:FiscalYearTwentyTwentyTwoMember2022-07-022022-09-300001076930us-gaap:CommonStockMember2023-07-012023-09-2900010769302023-09-290001076930novt:EmployeeRelatedMember2022-12-310001076930us-gaap:RevolvingCreditFacilityMember2022-12-310001076930srt:MaximumMemberus-gaap:WarrantyObligationsMember2023-01-012023-09-290001076930us-gaap:RetainedEarningsMember2022-07-010001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2023-01-012023-09-290001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001076930us-gaap:CorporateNonSegmentMember2022-07-022022-09-300001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2022-07-022022-09-300001076930novt:SeveranceFacilityRelatedAndOtherChargesMembernovt:FiscalYearTwentyTwentyTwoMember2023-01-012023-09-290001076930srt:MaximumMember2023-09-290001076930us-gaap:CorporateNonSegmentMember2022-01-012022-09-300001076930us-gaap:OperatingExpenseMember2023-09-290001076930novt:HybridPsusMember2023-01-012023-09-290001076930us-gaap:CommonStockMember2023-06-300001076930novt:EquityIncentivePlanTwentyTenMembersrt:MaximumMembernovt:HybridPsusMember2023-01-012023-09-290001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2023-07-012023-09-290001076930novt:MedicalSolutionsMember2022-12-310001076930us-gaap:RetainedEarningsMember2023-01-012023-09-290001076930srt:MaximumMembernovt:ProfessionalServicesMember2022-01-012022-09-300001076930srt:MinimumMember2023-01-012023-09-290001076930us-gaap:ResearchAndDevelopmentExpenseMember2022-07-022022-09-300001076930us-gaap:TechnologyBasedIntangibleAssetsMember2023-09-290001076930novt:EmployeeRelatedMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyMember2022-01-012022-09-300001076930novt:RestOfAsiaPacificMember2023-01-012023-09-290001076930country:CN2022-01-012022-09-300001076930country:CN2023-01-012023-09-290001076930us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-290001076930novt:SeveranceFacilityRelatedAndOtherChargesMembernovt:FiscalYearTwentyTwentyTwoMember2023-07-012023-09-290001076930country:DE2023-07-012023-09-290001076930us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930novt:SeveranceFacilityRelatedAndOtherChargesMembernovt:FiscalYearTwentyTwentyMember2023-07-012023-09-290001076930novt:RestOfAsiaPacificMember2022-07-022022-09-3000010769302023-07-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:PerformanceSharesMember2023-01-012023-09-2900010769302023-01-012023-09-290001076930novt:ARGESGmbHMember2021-03-012021-03-310001076930novt:FiscalYearTwentyTwentyTwoMembernovt:PrecisionMedicineAndManufacturingMember2023-07-012023-09-290001076930novt:AdvancedIndustrialMember2022-01-012022-09-300001076930novt:MedicalMember2023-07-012023-09-290001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2023-07-012023-09-290001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2023-01-012023-09-300001076930us-gaap:AccountingStandardsUpdate201409Member2023-01-012023-09-290001076930novt:TermLoanMember2023-09-290001076930srt:MaximumMemberus-gaap:LandMember2023-01-012023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-290001076930novt:RestOfEuropeMember2023-01-012023-09-2900010769302021-05-310001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2023-07-012023-09-290001076930novt:ARGESGmbHMember2021-12-310001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2022-01-012022-09-300001076930country:DE2023-01-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMembernovt:DeferredStockUnitsMember2023-09-290001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2023-07-012023-09-290001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2022-01-012022-09-300001076930novt:FiscalYearTwentyTwentyTwoMember2023-07-012023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-290001076930us-gaap:CorporateNonSegmentMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2023-07-012023-09-290001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2022-01-012022-09-300001076930novt:OtherCountriesMember2023-01-012023-09-290001076930us-gaap:RetainedEarningsMember2022-09-300001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2022-01-012022-09-300001076930srt:MaximumMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-12-3100010769302022-07-012022-09-300001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-290001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2023-07-012023-09-290001076930us-gaap:CommonStockMember2022-12-310001076930us-gaap:FairValueInputsLevel2Membernovt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930novt:TermLoanMember2022-12-310001076930us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-290001076930srt:MaximumMembernovt:ProfessionalServicesMember2023-01-012023-09-2900010769302023-10-300001076930us-gaap:CostOfSalesMember2022-07-022022-09-300001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001076930novt:ARGESGmbHMember2019-07-310001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930us-gaap:ForeignExchangeForwardMember2022-12-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-3000010769302022-01-012022-12-310001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-022022-09-300001076930us-gaap:WarrantyObligationsMember2023-01-012023-09-290001076930novt:MedicalMember2023-01-012023-09-290001076930us-gaap:RetainedEarningsMember2023-07-012023-09-290001076930us-gaap:FairValueInputsLevel3Member2022-12-310001076930novt:FiscalYearTwentyTwentyTwoMembernovt:RoboticsAndAutomationMember2023-07-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2022-12-3100010769302021-12-310001076930us-gaap:CommonStockMember2023-09-290001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FourthAmendmentRevolvingCreditFacilityMember2021-10-050001076930srt:MaximumMembernovt:FiscalYearTwentyTwentyTwoMember2023-09-290001076930us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001076930novt:UnallocatedCorporateAndSharedServicesMembernovt:FiscalYearTwentyTwentyTwoMember2023-01-012023-09-290001076930novt:PerformanceBasedRestrictedStockUnitsMember2023-09-290001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2022-12-310001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:FiscalYearTwentyTwentyTwoMember2023-09-290001076930us-gaap:RevolvingCreditFacilityMember2023-09-290001076930novt:TermLoanAndRevolvingCreditFacilityMember2022-12-310001076930us-gaap:AccumulatedTranslationAdjustmentMember2023-09-290001076930srt:MaximumMembernovt:EquityIncentivePlanTwentyTenMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-290001076930country:DE2022-01-012022-09-300001076930novt:OtherCountriesMember2022-01-012022-09-300001076930novt:FiscalYearTwentyTwentyTwoMembernovt:RoboticsAndAutomationMember2023-01-012023-09-290001076930us-gaap:FairValueInputsLevel3Member2023-01-012023-09-290001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-290001076930novt:AdvancedIndustrialMember2023-01-012023-09-290001076930novt:RestOfEuropeMember2022-01-012022-09-300001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:PerformanceSharesMember2023-09-290001076930us-gaap:ForeignExchangeForwardMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyTwoMembernovt:PrecisionMedicineAndManufacturingMember2022-01-012022-09-300001076930us-gaap:AdditionalPaidInCapitalMember2023-09-290001076930novt:HybridPsusMember2023-09-290001076930novt:EpsAndApplicableRelativeTsrPerformanceConditionsMember2023-01-012023-09-290001076930us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-290001076930srt:MinimumMemberus-gaap:WarrantyObligationsMember2023-01-012023-09-290001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:AdditionalPaidInCapitalMember2022-07-022022-09-300001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2022-01-012022-09-300001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:DirectorMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2022-01-012022-09-300001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2022-07-022022-09-300001076930us-gaap:FacilityClosingMember2022-12-310001076930us-gaap:CommonStockMember2021-12-310001076930us-gaap:TrademarksAndTradeNamesMember2022-12-310001076930novt:EmployeeRelatedMember2023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001076930us-gaap:OtherRestructuringMember2022-12-310001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2022-01-012022-09-300001076930novt:TermLoanAndRevolvingCreditFacilityMember2023-09-290001076930novt:EquityIncentivePlanTwentyTenMembersrt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyTwoMembernovt:MedicalSolutionsMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyTwoMember2023-01-012023-09-290001076930us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001076930novt:FiscalYearTwentyTwentyTwoMembernovt:PrecisionMedicineAndManufacturingMember2022-07-022022-09-300001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2023-01-012023-09-290001076930novt:ARGESGmbHMember2022-03-012022-03-310001076930novt:PerformanceBasedRestrictedStockUnitsMember2022-09-300001076930novt:FiscalYearTwentyTwentyMember2023-09-290001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FifthAmendmentRevolvingCreditFacilityMember2022-03-102022-03-100001076930novt:EquityIncentivePlanTwentyTenMember2023-01-012023-09-290001076930novt:OtherCountriesMember2023-07-012023-09-290001076930us-gaap:CustomerRelationshipsMember2023-09-290001076930novt:AttainmentBasedPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MinimumMember2023-01-012023-09-290001076930us-gaap:RetainedEarningsMember2022-12-310001076930us-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:AdditionalPaidInCapitalMember2022-12-310001076930novt:RestOfAsiaPacificMember2023-07-012023-09-290001076930us-gaap:CommonStockMember2022-01-012022-09-300001076930us-gaap:EmployeeStockOptionMember2023-01-012023-09-290001076930country:US2022-07-022022-09-300001076930country:US2023-01-012023-09-290001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2023-01-012023-09-290001076930us-gaap:CostOfSalesMember2023-01-012023-09-290001076930us-gaap:CommonStockMember2022-07-022022-09-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FifthAmendmentRevolvingCreditFacilityMember2022-03-100001076930novt:ProfessionalAndConsultingFeesMember2022-01-012022-09-300001076930novt:FiscalYearTwentyTwentyTwoMembernovt:PrecisionMedicineAndManufacturingMember2023-01-012023-09-290001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2020-02-290001076930us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-290001076930us-gaap:CommonStockMember2022-07-010001076930novt:ProfessionalAndConsultingFeesMember2022-07-022022-09-300001076930us-gaap:RetainedEarningsMember2023-06-300001076930novt:ProfessionalAndConsultingFeesMember2023-01-012023-09-2900010769302021-05-012021-05-310001076930novt:AdvancedIndustrialMember2022-07-022022-09-30iso4217:EURiso4217:USDxbrli:sharesxbrli:purenovt:EndMarketxbrli:sharesnovt:Segmentiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2023

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No.: 001-35083

NOVANTA INC.

(Exact name of registrant as specified in its charter)

New Brunswick, Canada

98-0110412

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

 

125 Middlesex Turnpike, Bedford, Massachusetts, USA

01730

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (781) 266-5700

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common shares, no par value

 

NOVT

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer

Accelerated filer

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 30, 2023, there were 35,810,370 of the Registrant’s common shares, no par value, issued and outstanding.

 

 


 

NOVANTA INC.

TABLE OF CONTENTS

Item No.

 

Page
No.

 

 

PART I — FINANCIAL INFORMATION

1

 

 

 

ITEM 1.

FINANCIAL STATEMENTS

1

 

 

 

CONSOLIDATED BALANCE SHEETS (unaudited)

1

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

2

 

 

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)

3

 

 

 

 

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited)

 

4

 

 

 

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

5

 

 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

6

 

 

 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

27

 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

39

 

 

 

ITEM 4.

CONTROLS AND PROCEDURES

39

 

 

PART II — OTHER INFORMATION

40

 

 

 

ITEM 1.

LEGAL PROCEEDINGS

40

 

 

 

ITEM 1A.

RISK FACTORS

40

 

 

 

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

40

 

 

 

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

40

 

 

 

ITEM 4.

MINE SAFETY DISCLOSURES

41

 

 

 

ITEM 5.

OTHER INFORMATION

41

 

 

 

ITEM 6.

EXHIBITS

41

 

 

SIGNATURES

43

 

 

 

 


 

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVANTA INC.

CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars or shares)

(Unaudited)

 

September 29,

 

 

December 31,

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

75,961

 

 

$

100,105

 

Accounts receivable, net of allowance of $1,307 and $995, respectively

 

143,086

 

 

 

137,697

 

Inventories

 

153,809

 

 

 

167,997

 

Prepaid income taxes and income taxes receivable

 

5,299

 

 

 

1,508

 

Prepaid expenses and other current assets

 

13,167

 

 

 

13,212

 

Total current assets

 

391,322

 

 

 

420,519

 

Property, plant and equipment, net

 

103,323

 

 

 

103,186

 

Operating lease assets

 

40,527

 

 

 

43,317

 

Deferred tax assets

 

24,714

 

 

 

15,113

 

Other assets

 

5,653

 

 

 

4,414

 

Intangible assets, net

 

151,096

 

 

 

175,766

 

Goodwill

 

477,642

 

 

 

478,897

 

Total assets

$

1,194,277

 

 

$

1,241,212

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities

 

 

 

 

 

Current portion of long-term debt

$

4,736

 

 

$

4,800

 

Accounts payable

 

63,983

 

 

 

75,225

 

Income taxes payable

 

7,223

 

 

 

13,660

 

Current portion of operating lease liabilities

 

8,072

 

 

 

7,793

 

Accrued expenses and other current liabilities

 

54,375

 

 

 

63,044

 

Total current liabilities

 

138,389

 

 

 

164,522

 

Long-term debt

 

347,879

 

 

 

430,662

 

Operating lease liabilities

 

38,577

 

 

 

40,808

 

Deferred tax liabilities

 

14,439

 

 

 

17,194

 

Income taxes payable

 

4,932

 

 

 

4,355

 

Other liabilities

 

5,205

 

 

 

6,085

 

Total liabilities

 

549,421

 

 

 

663,626

 

Commitments and contingencies (Note 14)

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Preferred shares, no par value; Authorized shares: 7,000;
   
No shares issued and outstanding

 

 

 

 

 

Common shares, no par value; Authorized shares: unlimited;
   Issued and outstanding:
35,810 and 35,711, respectively

 

423,856

 

 

 

423,856

 

Additional paid-in capital

 

63,362

 

 

 

55,155

 

Retained earnings

 

190,951

 

 

 

130,584

 

Accumulated other comprehensive loss

 

(33,313

)

 

 

(32,009

)

Total stockholders' equity

 

644,856

 

 

 

577,586

 

Total liabilities and stockholders’ equity

$

1,194,277

 

 

$

1,241,212

 

 

The accompanying notes are an integral part of these consolidated financial statements.

1


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 29,

 

 

September 30,

 

 

September 29,

 

 

September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue

$

221,503

 

 

$

222,958

 

 

$

670,093

 

 

$

642,530

 

Cost of revenue

 

119,912

 

 

 

124,550

 

 

 

366,751

 

 

 

358,601

 

Gross profit

 

101,591

 

 

 

98,408

 

 

 

303,342

 

 

 

283,929

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development and engineering

 

22,022

 

 

 

21,349

 

 

 

68,230

 

 

 

63,866

 

Selling, general and administrative

 

39,648

 

 

 

40,301

 

 

 

122,758

 

 

 

120,191

 

Amortization of purchased intangible assets

 

5,131

 

 

 

6,472

 

 

 

15,344

 

 

 

20,987

 

Restructuring, acquisition, and related costs

 

4,481

 

 

 

1,625

 

 

 

8,191

 

 

 

2,650

 

Total operating expenses

 

71,282

 

 

 

69,747

 

 

 

214,523

 

 

 

207,694

 

Operating income

 

30,309

 

 

 

28,661

 

 

 

88,819

 

 

 

76,235

 

Interest income (expense), net

 

(6,756

)

 

 

(4,062

)

 

 

(19,898

)

 

 

(9,928

)

Foreign exchange transaction gains (losses), net

 

(370

)

 

 

2,086

 

 

 

(373

)

 

 

2,307

 

Other income (expense), net

 

(189

)

 

 

87

 

 

 

(546

)

 

 

(390

)

Income before income taxes

 

22,994

 

 

 

26,772

 

 

 

68,002

 

 

 

68,224

 

Income tax provision

 

1,771

 

 

 

4,282

 

 

 

7,635

 

 

 

9,435

 

Consolidated net income

$

21,223

 

 

$

22,490

 

 

$

60,367

 

 

$

58,789

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per common share (Note 4):

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.59

 

 

$

0.63

 

 

$

1.68

 

 

$

1.65

 

Diluted

$

0.59

 

 

$

0.63

 

 

$

1.68

 

 

$

1.64

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic

 

35,856

 

 

 

35,729

 

 

 

35,839

 

 

 

35,625

 

Weighted average common shares outstanding—diluted

 

36,041

 

 

 

35,928

 

 

 

36,024

 

 

 

35,881

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands of U.S. dollars)

(Unaudited)

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 29,

 

 

September 30,

 

 

September 29,

 

 

September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Consolidated net income

$

21,223

 

 

$

22,490

 

 

$

60,367

 

 

$

58,789

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments, net of tax (1)

 

(8,786

)

 

 

(18,972

)

 

 

(1,980

)

 

 

(37,672

)

Pension liability adjustments, net of tax (2)

 

515

 

 

 

710

 

 

 

676

 

 

 

1,611

 

Total other comprehensive income (loss)

 

(8,271

)

 

 

(18,262

)

 

 

(1,304

)

 

 

(36,061

)

Total consolidated comprehensive income

$

12,952

 

 

$

4,228

 

 

$

59,063

 

 

$

22,728

 

 

(1)
The tax effect on this component of comprehensive income (loss) was nominal for all periods presented.
(2)
The tax effect on this component of comprehensive income (loss) was nominal for all periods presented. See Note 3 to the Consolidated Financial Statements for the total amount of pension liability adjustments reclassified out of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

 

3


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands of U.S. dollars or shares)

(Unaudited)

 

 

Common Shares

 

 

Additional Paid-In

 

 

Retained

 

 

Accumulated Other

 

 

 

 

 

# of Shares

 

 

Amount

 

 

Capital

 

 

Earnings

 

 

Comprehensive Loss

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 29, 2023

 

Balance at June 30, 2023

 

35,808

 

 

$

423,856

 

 

$

57,488

 

 

$

169,728

 

 

$

(25,042

)

 

$

626,030

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

21,223

 

 

 

 

 

 

21,223

 

Common shares issued under stock plans

 

3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(1

)

 

 

 

 

 

(163

)

 

 

 

 

 

 

 

 

(163

)

Share-based compensation

 

 

 

 

 

 

 

6,037

 

 

 

 

 

 

 

 

 

6,037

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,271

)

 

 

(8,271

)

Balance at September 29, 2023

 

35,810

 

 

$

423,856

 

 

$

63,362

 

 

$

190,951

 

 

$

(33,313

)

 

$

644,856

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 29, 2023

 

Balance at December 31, 2022

 

35,711

 

 

$

423,856

 

 

$

55,155

 

 

$

130,584

 

 

$

(32,009

)

 

$

577,586

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

60,367

 

 

 

 

 

 

60,367

 

Common shares issued under stock plans

 

167

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(68

)

 

 

 

 

 

(10,171

)

 

 

 

 

 

 

 

 

(10,171

)

Share-based compensation

 

 

 

 

 

 

 

18,378

 

 

 

 

 

 

 

 

 

18,378

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,304

)

 

 

(1,304

)

Balance at September 29, 2023

 

35,810

 

 

$

423,856

 

 

$

63,362

 

 

$

190,951

 

 

$

(33,313

)

 

$

644,856

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 2022

 

Balance at July 1, 2022

 

35,623

 

 

$

423,856

 

 

$

46,146

 

 

$

92,832

 

 

$

(30,665

)

 

$

532,169

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

22,490

 

 

 

 

 

 

22,490

 

Common shares issued under stock plans

 

67

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(1

)

 

 

 

 

 

(149

)

 

 

 

 

 

 

 

 

(149

)

Repurchases of common shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

 

 

 

 

 

5,954

 

 

 

 

 

 

 

 

 

5,954

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

(18,262

)

 

 

(18,262

)

Balance at September 30, 2022

 

35,689

 

 

$

423,856

 

 

$

51,951

 

 

$

115,322

 

 

$

(48,927

)

 

$

542,202

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2022

 

Balance at December 31, 2021

 

35,601

 

 

$

423,856

 

 

$

53,768

 

 

$

56,533

 

 

$

(12,866

)

 

$

521,291

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

58,789

 

 

 

 

 

 

58,789

 

Common shares issued under stock plans

 

238

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(66

)

 

 

 

 

 

(9,626

)

 

 

 

 

 

 

 

 

(9,626

)

Repurchases of common shares

 

(84

)

 

 

 

 

 

(10,000

)

 

 

 

 

 

 

 

 

(10,000

)

Share-based compensation

 

 

 

 

 

 

 

17,809

 

 

 

 

 

 

 

 

 

17,809

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

(36,061

)

 

 

(36,061

)

Balance at September 30, 2022

 

35,689

 

 

$

423,856

 

 

$

51,951

 

 

$

115,322

 

 

$

(48,927

)

 

$

542,202

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

4


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(Unaudited)

 

Nine Months Ended

 

 

September 29,

 

 

September 30,

 

 

2023

 

 

2022

 

Cash flows from operating activities:

 

 

 

 

 

Consolidated net income

$

60,367

 

 

$

58,789

 

Adjustments to reconcile consolidated net income to
   net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

35,065

 

 

 

40,999

 

Provision for inventory excess and obsolescence

 

6,563

 

 

 

1,940

 

Impairment of assets

 

1,421

 

 

 

 

Share-based compensation

 

18,378

 

 

 

17,809

 

Deferred income taxes

 

(12,328

)

 

 

(14,628

)

Write-off of unamortized deferred financing costs

 

 

 

 

624

 

Other

 

1,289

 

 

 

(152

)

Changes in assets and liabilities which (used)/provided cash, excluding
   effects from business acquisitions:

 

 

 

 

 

Accounts receivable

 

(6,371

)

 

 

(34,444

)

Inventories

 

5,619

 

 

 

(46,552

)

Prepaid income taxes, income taxes receivable, prepaid expenses
     and other current assets

 

(3,444

)

 

 

(